# Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control

Study · id `cardio:ct-nct01932450` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01932450](<https://clinicaltrials.gov/study/NCT01932450>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01932450

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01932450. Randomized; no masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01932450, source copy `cardio:ctgov-nct01932450-2014-09-25`, retrieved 2026-10-26)
- Start date: 2013-08 (registry gives no type) (ClinicalTrials.gov record NCT01932450, source copy `cardio:ctgov-nct01932450-2014-09-25`, retrieved 2026-10-26)
- Primary completion: 2014-12 (anticipated) (ClinicalTrials.gov record NCT01932450, source copy `cardio:ctgov-nct01932450-2014-09-25`, retrieved 2026-10-26)
- Completion: 2015-07 (anticipated) (ClinicalTrials.gov record NCT01932450, source copy `cardio:ctgov-nct01932450-2014-09-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01932450, source copy `cardio:ctgov-nct01932450-2014-09-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01932450-2014-09-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control
- Acronym: RAFALE
- Condition: Autosomal Dominant Polycystic Kidney Disease
- Condition: Hypertension
- Intervention (Procedure): renal sympathetic denervation
- Intervention (Drug): antihypertensive drugs
- Lead sponsor: Mei changlin
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: a682af10494bd27c167805ed904c701986f05b4f3792177ee79659b471e79e3c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
